Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Stellar Biotechnologies (SBOT) Competitors

Stellar Biotechnologies logo

SBOT vs. SLRN, CYBN, NLTX, BIOA, PROC, OPTN, WHWK, VIRI, VHAQ, and PYRGF

Should you be buying Stellar Biotechnologies stock or one of its competitors? The main competitors of Stellar Biotechnologies include Acelyrin (SLRN), Cybin (CYBN), Neoleukin Therapeutics (NLTX), BioAge Labs (BIOA), Procaps Group (PROC), OptiNose (OPTN), Whitehawk Therapeutics (WHWK), Virios Therapeutics (VIRI), Viveon Health Acquisition (VHAQ), and PyroGenesis Canada (PYRGF).

Stellar Biotechnologies vs. Its Competitors

Acelyrin (NASDAQ:SLRN) and Stellar Biotechnologies (NASDAQ:SBOT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

87.3% of Acelyrin shares are owned by institutional investors. Comparatively, 1.7% of Stellar Biotechnologies shares are owned by institutional investors. 13.6% of Acelyrin shares are owned by insiders. Comparatively, 7.8% of Stellar Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Acelyrin has a net margin of 0.00% compared to Stellar Biotechnologies' net margin of -1,782.64%. Acelyrin's return on equity of -44.12% beat Stellar Biotechnologies' return on equity.

Company Net Margins Return on Equity Return on Assets
AcelyrinN/A -44.12% -39.02%
Stellar Biotechnologies -1,782.64%-51.12%-48.37%

Acelyrin currently has a consensus target price of $9.60, indicating a potential upside of 322.91%. Given Acelyrin's stronger consensus rating and higher probable upside, analysts clearly believe Acelyrin is more favorable than Stellar Biotechnologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acelyrin
0 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.40
Stellar Biotechnologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Acelyrin's average media sentiment score of 0.00 equaled Stellar Biotechnologies'average media sentiment score.

Company Overall Sentiment
Acelyrin Neutral
Stellar Biotechnologies Neutral

Stellar Biotechnologies has higher revenue and earnings than Acelyrin. Stellar Biotechnologies is trading at a lower price-to-earnings ratio than Acelyrin, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AcelyrinN/AN/A-$381.64M-$2.69-0.84
Stellar Biotechnologies$210K254.82-$5.03M-$1.76-5.70

Summary

Acelyrin beats Stellar Biotechnologies on 9 of the 12 factors compared between the two stocks.

Get Stellar Biotechnologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for SBOT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SBOT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SBOT vs. The Competition

MetricStellar BiotechnologiesPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$53.51M$881.03M$5.62B$9.10B
Dividend YieldN/A4.84%5.24%4.00%
P/E Ratio-5.701.3828.0520.27
Price / Sales254.82241.37429.5999.27
Price / CashN/A17.6937.4658.16
Price / Book4.746.588.055.49
Net Income-$5.03M-$23.83M$3.18B$250.45M

Stellar Biotechnologies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SBOT
Stellar Biotechnologies
N/A$10.04
-5.5%
N/A+346.2%$53.51M$210K-5.7025
SLRN
Acelyrin
N/A$2.27
flat
$9.60
+322.9%
N/A$229.17MN/A-0.92135
CYBN
Cybin
2.8215 of 5 stars
$8.39
+2.9%
$86.00
+925.0%
N/A$193.17MN/A-1.9250Analyst Forecast
NLTX
Neoleukin Therapeutics
N/A$16.16
-2.5%
N/A-49.1%$151.87MN/A-5.2090High Trading Volume
BIOA
BioAge Labs
N/A$4.13
-1.7%
N/AN/A$150.57MN/A0.00N/A
PROC
Procaps Group
N/A$0.95
-40.3%
N/A-62.2%$107.18M$409.92M0.004,900Gap Down
High Trading Volume
OPTN
OptiNose
0.6578 of 5 stars
$9.60
flat
$9.00
-6.3%
N/A$97.22M$81.86M-2.29190
WHWK
Whitehawk Therapeutics
N/A$1.87
-3.1%
N/AN/A$90.92M$25.98M0.0040
VIRI
Virios Therapeutics
N/A$4.71
-1.3%
$5.00
+6.2%
+1,936.7%$90.71MN/A-17.445
VHAQ
Viveon Health Acquisition
N/A$11.00
flat
N/AN/A$62.26MN/A0.002High Trading Volume
PYRGF
PyroGenesis Canada
0.0929 of 5 stars
$0.33
+0.8%
N/A-55.0%$61.14M$9.14M-5.5090News Coverage
High Trading Volume

Related Companies and Tools


This page (NASDAQ:SBOT) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners